Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12595307rdf:typepubmed:Citationlld:pubmed
pubmed-article:12595307lifeskim:mentionsumls-concept:C0023418lld:lifeskim
pubmed-article:12595307lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:12595307lifeskim:mentionsumls-concept:C0927232lld:lifeskim
pubmed-article:12595307lifeskim:mentionsumls-concept:C1517806lld:lifeskim
pubmed-article:12595307lifeskim:mentionsumls-concept:C0939537lld:lifeskim
pubmed-article:12595307pubmed:issue12lld:pubmed
pubmed-article:12595307pubmed:dateCreated2003-6-5lld:pubmed
pubmed-article:12595307pubmed:abstractTextThe chronic myelogenous leukemia (CML)-like myeloproliferative disorder observed in the BCR/ABL murine bone marrow transduction and transplantation model shares several features with the human disease, including a high response rate to the tyrosine kinase inhibitor imatinib mesylate (STI571). To study the impact of chronic imatinib mesylate treatment on the CML-like illness, mice were maintained on therapeutic doses of this drug and serially monitored. Unexpectedly, despite excellent systemic control of the CML-like illness, many of the mice developed progressive neurologic deficits after 2 to 4 months of imatinib mesylate therapy because of central nervous system (CNS) leukemia. Analysis of imatinib mesylate cerebral spinal fluid concentrations revealed levels 155- fold lower than in plasma. Thus, in the mouse, the limited ability of imatinib mesylate to cross the blood-brain barrier allowed the CNS to become a sanctuary for Bcr/Abl-induced leukemia. This model will be a useful tool for the future study of novel anti-CML drugs and in better defining the mechanisms for limited imatinib mesylate penetration into the CNS.lld:pubmed
pubmed-article:12595307pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12595307pubmed:languageenglld:pubmed
pubmed-article:12595307pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12595307pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12595307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12595307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12595307pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12595307pubmed:statusMEDLINElld:pubmed
pubmed-article:12595307pubmed:monthJunlld:pubmed
pubmed-article:12595307pubmed:issn0006-4971lld:pubmed
pubmed-article:12595307pubmed:authorpubmed-author:RichardsonJam...lld:pubmed
pubmed-article:12595307pubmed:authorpubmed-author:IlariaRobert...lld:pubmed
pubmed-article:12595307pubmed:authorpubmed-author:WolffNicholas...lld:pubmed
pubmed-article:12595307pubmed:authorpubmed-author:EgorinMerrill...lld:pubmed
pubmed-article:12595307pubmed:issnTypePrintlld:pubmed
pubmed-article:12595307pubmed:day15lld:pubmed
pubmed-article:12595307pubmed:volume101lld:pubmed
pubmed-article:12595307pubmed:ownerNLMlld:pubmed
pubmed-article:12595307pubmed:authorsCompleteYlld:pubmed
pubmed-article:12595307pubmed:pagination5010-3lld:pubmed
pubmed-article:12595307pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:meshHeadingpubmed-meshheading:12595307...lld:pubmed
pubmed-article:12595307pubmed:year2003lld:pubmed
pubmed-article:12595307pubmed:articleTitleThe CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.lld:pubmed
pubmed-article:12595307pubmed:affiliationDivision of Hematology/Oncology, Department of Medicine, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas 75390, USA.lld:pubmed
pubmed-article:12595307pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12595307pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12595307pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12595307lld:pubmed